Inovio Pharma (INO) Attacking 'Significant' Unmet Need with Flu Imitative; Aegis Maintains at 'Buy'
Tweet Send to a Friend
Aegis Capital affirms Inovio Pharma (Nasdaq: INO) at Buy with a price target of $19 following news that the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
